摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(1,3-benzodioxol-5-ylmethyl)-1H-quinazoline-2,4-dione | 214749-92-5

中文名称
——
中文别名
——
英文名称
3-(1,3-benzodioxol-5-ylmethyl)-1H-quinazoline-2,4-dione
英文别名
——
3-(1,3-benzodioxol-5-ylmethyl)-1H-quinazoline-2,4-dione化学式
CAS
214749-92-5
化学式
C16H12N2O4
mdl
MFCD05032477
分子量
296.282
InChiKey
RRHWHVALNDQRDZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    262-263.5 °C(Solv: ethanol (64-17-5))
  • 密度:
    1.439±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    67.9
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • A practical solid phase synthesis of quinazoline-2,4-diones
    作者:Hui Shao、Marcus Colucci、Shaojing Tong、Hesheng Zhang、Arlindo L. Castelhano
    DOI:10.1016/s0040-4039(98)01595-0
    日期:1998.10
    We describe a practical solid phase synthesis of quinazoline-2,4-diones using a short-chain, high loading capacity, polyethyleneglycol polystyrene copolymer ("PEG(4)-PS" resin). The highlights of this synthesis include efficient acyl azide formation on the solid phase, Curtius rearrangement, and cyclocleavage with K2CO3 followed by simple product isolation. (C) 1998 Elsevier Science Ltd. All rights reserved.
  • COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB
    申请人:Warner-Lambert Company LLC
    公开号:EP1530467A2
    公开(公告)日:2005-05-18
  • [EN] COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB<br/>[FR] COMBINAISON D'UN INHIBITEUR CARBOXYLIQUE ALLOSTERIQUE DE METALLOPROTEINASE-13 DE MATRICE ET DE CELECOXIBE OU DE VALDECOXIBE
    申请人:WARNER LAMBERT CO
    公开号:WO2004006912A2
    公开(公告)日:2004-01-22
    This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.
  • L'inhibition de l'aldose réductase par des dérivés 2,4-oxo et thioxo de la 1,2,3,4-tétrahydro quinazoline
    作者:F Billon
    DOI:10.1016/0223-5234(90)90019-y
    日期:1990.3
查看更多